Ultragenyx Pharmaceutical Inc RARE Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$15.43 down $0.14, 0.90% at close Nov 6
Last close · Previous close $15.57
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$5.18Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$15.43down $0.14, 0.90%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$15.57Nov 5
- Volume4.05MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume3.56MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $12.73 to $39.89; now $15.43
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
RARE beat the S&P 500 in 1 of 7 periods.
| Period | RARE and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RARE: up 6.7% S&P 500: down 5.6% | RARE beat the S&P 500 by 12.3 percentage points Beat |
| 3M | RARE: down 40.2% S&P 500: down 4.1% | RARE trailed the S&P 500 by 36.1 percentage points Trailed |
| YTD | RARE: down 32.9% S&P 500: up 8.7% | RARE trailed the S&P 500 by 41.6 percentage points Trailed |
| 1Y | RARE: down 50.1% S&P 500: up 10.9% | RARE trailed the S&P 500 by 61.0 percentage points Trailed |
| Long term | ||
| 3Y | RARE: down 59.2% S&P 500: up 75.0% −25.8% vs +20.5% a year | RARE trailed the S&P 500 by 134.2 percentage points Trailed |
| 5Y | RARE: down 81.5% S&P 500: up 67.8% −28.6% vs +10.9% a year | RARE trailed the S&P 500 by 149.3 percentage points Trailed |
| 10Y | RARE: down 72.1% S&P 500: up 313.1% −12.0% vs +15.2% a year | RARE trailed the S&P 500 by 385.2 percentage points Trailed |
$10,000 invested in RARE 10 years ago (Nov 4, 2016) would be worth about $2,793 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
RARE beat the S&P 500 in 1 of 7 periods.
| Period | RARE and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RARE: up 6.7% S&P 500: down 5.6% | RARE beat the S&P 500 by 12.3 percentage points Beat |
| 3M | RARE: down 40.2% S&P 500: down 4.3% | RARE trailed the S&P 500 by 35.9 percentage points Trailed |
| YTD | RARE: down 32.9% S&P 500: up 7.8% | RARE trailed the S&P 500 by 40.7 percentage points Trailed |
| 1Y | RARE: down 50.1% S&P 500: up 9.7% | RARE trailed the S&P 500 by 59.8 percentage points Trailed |
| Long term | ||
| 3Y | RARE: down 59.2% S&P 500: up 68.8% −25.8% vs +19.1% a year | RARE trailed the S&P 500 by 128.0 percentage points Trailed |
| 5Y | RARE: down 81.5% S&P 500: up 56.9% −28.6% vs +9.4% a year | RARE trailed the S&P 500 by 138.4 percentage points Trailed |
| 10Y | RARE: down 72.1% S&P 500: up 252.6% −12.0% vs +13.4% a year | RARE trailed the S&P 500 by 324.7 percentage points Trailed |
$10,000 invested in RARE 10 years ago (Nov 4, 2016) would be worth about $2,793 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$177.39
Closing high on . Now 91.3% below that record.
Split-adjusted daily closes since Jan 31, 2014.
Stock splits
RARE hasn’t split since its price history begins in 2014.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $730.28Mup 15.8%
- Net income
- −$523.56M
- Diluted EPS
- −$5.18
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $164.65M | −$133.20M | −$1.38 |
| Q1 FY25 (Mar 31, 2025) | $139.00M | −$151.00M | −$1.57 |
| Q2 FY25 (Jun 30, 2025) | $167.00M | −$115.00M | −$1.17 |
| Q3 FY25 (Sep 30, 2025) | $160.00M | −$180.00M | −$1.81 |
| Q4 FY25 (Dec 31, 2025) | $207.28M | −$128.56M | −$1.28 |
| Q1 FY26 (Mar 31, 2026) | $136.00M | −$185.00M | −$1.84 |
| Q2 FY26 (Jun 30, 2026) | $214.00M | −$92.00M | −$0.90 |
| Q3 FY26 (Sep 30, 2026) | $173.00M | −$118.00M | −$1.16 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $351.41M | −$454.03M | −$6.70 |
| FY22 (Dec 31, 2022) | $363.33M | −$707.42M | −$10.12 |
| FY23 (Dec 31, 2023) | $434.00M | −$607.00M | −$8.25 |
| FY24 (Dec 31, 2024) | $560.00M | −$569.00M | −$6.29 |
| FY25 (Dec 31, 2025) | $673.00M | −$575.00M | −$5.83 |
Margins
- Gross 82.8%
- Operating −64.0%
- Net −71.7%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$441.77MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$436.83MLast 12 months
- Capital spending$4.94MLast 12 months
- −60.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $2.19MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $401.00MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$1.19BAs of Sep 30, 2026
- Net debt$785.00MAs of Sep 30, 2026
- 1.40As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −39.7%Last 12 months
Over the last 12 months, Ultragenyx Pharmaceutical’s net loss was 39.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Ultragenyx Pharmaceutical Inc
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
RARE news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
RARE stock FAQ
What is RARE stock’s price today?
Ultragenyx Pharmaceutical (RARE) traded at $15.43 at the close on , down $0.14 (0.90%) from the previous close of $15.57. Over the past 52 weeks it has traded between $12.73 and $39.89.
If you invested $1,000 in RARE 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in RARE on would be worth about $279 at the close on , a total return of −72.1%. The same $1,000 would be worth $185 if invested five years ago and $499 if invested one year ago. Past performance doesn’t predict future returns.
What is RARE’s P/E ratio?
RARE’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$5.18).
How much revenue does Ultragenyx Pharmaceutical make?
Ultragenyx Pharmaceutical reported $730.3 million of revenue over the four quarters to , up 15.8% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $173.0 million, up 8.1% from a year earlier.
Is Ultragenyx Pharmaceutical profitable?
Not over the four quarters to . Ultragenyx Pharmaceutical reported a net loss of $523.6 million across those four quarters on $730.3 million of revenue.
What are RARE’s earnings per share?
RARE’s diluted earnings per share were −$5.18 over the four quarters to , compared with −$5.93 in the twelve months before. The latest quarter (Q3 FY26) brought −$1.16 per share, against −$1.81 a year earlier (how EPS works).
Does RARE pay a dividend?
Ultragenyx Pharmaceutical hasn’t paid a dividend in the last twelve months.
What is RARE’s 52-week high and low?
Over the past 52 weeks RARE has traded as low as $12.73 and as high as $39.89. At $15.43 at the close on , it is 61.3% below that high and 21.2% above the low.
What is RARE’s all-time high?
RARE’s highest closing price was $177.39 on , adjusted for stock splits. At $15.43 at the close on , it is 91.3% below that record.
Has RARE stock ever split?
No. RARE hasn’t split since its price history begins in 2014.
How has RARE stock performed?
Including dividends and measured to the close on , RARE has returned −32.9% so far this year and −50.1% over the past year, and −81.5% over five years (−28.6% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Ultragenyx Pharmaceutical in?
Ultragenyx Pharmaceutical is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does RARE trade on?
Ultragenyx Pharmaceutical trades on the Nasdaq under the ticker symbol RARE. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.